Skip to main content

The Impact of Sex on the Immunogenicity of a Bivalent Meningococcal Serogroup B Vaccine: A Systematic Review and Meta-Analysis of Individual Participant Data

In brief

Men show 10% higher antibody responses after meningococcal B vaccination

In pooled data from 12 trials involving 18,221 people aged 1 to 29, males had about 10% higher antibody levels after at least two doses of a bivalent meningococcal B vaccine, and higher odds of reaching the study's seroprotection threshold. The difference was modest and does not support separate vaccination schedules by sex; long-term antibody levels and booster responses remain unclear.

Journal
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (Q1)
Published
18 November 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Anthony Willems, Bart Jacobs, Simon De Gussem, Geert Leroux-Roels, Isabel Leroux-Roels, Valentino D'Onofrio
PMID
43051532
DOI
10.1016/j.cmi.2026.10.041

Why clinicians should know about it

  • Picked for Immunology and Allergy (top studies of the week, 22 November 2026): Vaccine immunogenicity meta-analysis identifies sex differences in protection

Abstract

BACKGROUND: Biological sex is a recognized biological factor influencing vaccine-induced immune responses. Differences in sex hormones and other biological determinants may contribute to variability in vaccine immunogenicity. However, the extent to which biological sex and other host-, vaccine- and study-related factors affect MenB-FHbp vaccine immunogenicity remains insufficiently understood. OBJECTIVES: To evaluate the association between biological sex and MenB-FHbp vaccine-induced immunogenicity and seroprotection, while accounting for established determinants of immune response. DATA SOURCES: Pubmed, Embase, Web of Science, and the Cochrane Library were searched up to February 7, 2024, and updated on June 22, 2026. STUDY ELIGIBILITY CRITERIA: Randomized controlled trials reporting human serum bactericidal assay (hSBA) immunogenicity after ≥ two MenB-FHbp doses in participants aged 1-29 years. PARTICIPANTS: MenB-FHbp vaccinated participants receiving ≥ two doses. INTERVENTIONS: MenB-FHbp administered in ≥ two-dose schedules at varying vaccine doses. ASSESSMENT RISK OF BIAS: Risk of bias was evaluated using the Cochrane RoB 2 tool. METHODS OF DATA SYNTHESIS: Individual participant data (IPD) from eligible trials were pooled and analysed using multivariable linear and logistic mixed-effects models adjusted for covariates. Missing data were addressed using multiple imputation. RESULTS: Twelve eligible MenB-FHbp trials comprising 18,221 participants were included. Males showed higher post-vaccination hSBA responses than females. After adjustment for covariates, males remained independently associated with higher log10-transformed hSBA titres (estimate 0.04 [0.03-0.05]), corresponding to approximately 10% higher geometric mean titres. Males also had higher odds of achieving seroprotection (OR 1.34 [1.26-1.42]). A study-level meta-analysis demonstrated a pooled mean difference of 0.05 [0.03-0.08], with low heterogeneity (I2=6.3%). CONCLUSION: Biological sex is an independent determinant of MenB-FHbp immunogenicity, with males exhibiting modestly higher antibody responses and seroprotection rates than females. Although these differences are unlikely to warrant sex-specific vaccination strategies, future studies should evaluate long-term antibody persistence and booster responses using sex-stratified analyses.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.